Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25298000 | 0.86 | ACACB (0.39) | SCN9AGABRA5MTNR1AMTNR1BLMNA | |
| SCHEMBL25298001 | 0.86 | ACACB (0.39) | SCN9AGABRA5MTNR1AMTNR1BLMNA | |
| SCHEMBL25295581 | 0.84 | AAK1 (0.44) | SCN9AGABRA5AAK1CNR2 | |
| SCHEMBL25295580 | 0.84 | AAK1 (0.44) | SCN9AGABRA5AAK1CNR2 | |
| SCHEMBL25300548 | 0.84 | SCN9A (0.37) | SCN9AGABRA5AAK1LMNASMN1; SMN2 | |
| SCHEMBL25252925 | 0.84 | SCN9A (0.37) | SCN9AGABRA5AAK1LMNASMN1; SMN2 | |
| SCHEMBL25811104 | 0.83 | AAK1 (0.50) | SCN9AAAK1 | |
| SCHEMBL25291590 | 0.81 | MTNR1A (0.38) | GABRA5MTNR1AMTNR1BLMNAHPGD | |
| SCHEMBL25291591 | 0.81 | MTNR1A (0.38) | GABRA5MTNR1AMTNR1BLMNAHPGD | |
| SCHEMBL25807350 | 0.78 | SCN9A (0.43) | SCN9AAAK1LMNASMN1; SMN2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | SCN9A 2882/4885GABRA5 1863/4885AAK1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.